Spyre Therapeutics, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 424B5, Offering prospectusOct 5 →InsidersNo open-market buys. 8 insiders sold $422.1M, 44 of 45 sales on a 10b5-1 plan.→HoldersFMR 14.8%BlackRock 7.4%Perceptive 4.9%→Financing →PeersClosest companies: TECX, ALMS, CGEM→
From the filings
Figures
- Revenue
- $0.00last 12 months
- Net income
- −$178.9Mlast 12 months
- Operating cash flow
- −$185.6Mlast 12 months
- Cash and equivalents
- $162.0Mat the last balance sheet
- Shares outstanding
- 88.1M shareson issue